drugset

drugset / Trial / NCT06606093

Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients

NCT06606093 ↗

Phase 3 Not yet recruiting 348 enrolled Daewoong Pharmaceutical Co. LTD.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to evaluate the efficacy and safety of DWP16001 in type 2 diabetic nephropathy with moderate renal impairment patients (CKD stage 3)

Timeline

Start: 2024-09-23
Primary completion: 2026-09-01
Completion: 2027-01-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Enavogliflozin	Small molecule	0.3 mg	Oral

Indications